CDER Ad Division Does Not Need Larger Staff, PhRMA Tells FDLI
FDA's Division of Drug, Marketing & Communications should not increase the size of its advertising review staff, PhRMA General Counsel Russel Bantham told a Food & Drug Law Institute conference in Washington, D.C. April 18.
You may also be interested in...
Drug approval times will be one topic of interest at the House Energy & Commerce/Health Subcommittee's May 3 hearing kicking off the user fee reauthorization process, Commerce Committee Majority Counsel Brent Del Monte told the Food & Drug Law Institute conference April 18 in Washington, D.C.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011